**MINUTES**

**CPIC CONFERENCE CALL**

DATE: October 4, 2018

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress  | Guideline updates in progress:* *TPMT/NUDT15/*thiopurines*-* In review with CPT
* *CYP2C9/HLA/*phenytoin: Drafting recommendation
* *CYP2D6*/codeine: Authorship plan underway

New guidelines in progress: * *RYR1*/inhaled anesthetics: In review with CPT
* *CYP2B6*/efavirenz: See below
* *CYP2D6/*atomoxetine: See below
* *CYP2C19/*PPI: Evidence review underway
* *CYP2C9/*celecoxib: Evidence review underway
 | Guideline preparation will continue and Kelly will continue to follow-up. |
| CYP2B6/efavirenz guideline | David Haas presented Tables 1 (genotype to phenotype) and 2 (recommendation) of the *CYP2B6*/efavirenz draft. Members discussed the guideline, specifically about information regarding how to use the dosing recommendation if a patient is taking the three-in-one pill (Atripla). Authors have addressed this concern in the guideline but will try to address in the recommendation table as well. This guideline will be sent out for CPIC review in the near future. Authors are still working to draft a pediatric recommendation and working on implementation figures/tables. | Kelly will follow-up. |
| CYP2D6/atomoxetine | Jacob Brown presented the Tables 1 (genotype to phenotype), 2 (pediatric recommendation), and 3 (adult recommendation) for the *CYP2D6*/atomoxetine guideline. It was noted that because the *CYP2D6* genotype to phenotype standardization project is ongoing, we will use the the current system (Gaedigk allele score system) in this guideline with the exception of \*10 (AS of 1 when \*10 allele is present has a separate recommendation compared to AS of 1 without the \*10 allele). This guideline will be sent out for CPIC review in the near future. Authors are in the process of finalizing the draft and working on the implementation figures/tables.  | Kelly will follow-up. |
| CPIC meeting | CPIC is tentatively planning a CPIC meeting that will be held in early June 2019 at St. Jude Children’s Research Hospital in Memphis, TN, but dates are still not finalized. A planning committee will be formed but if you have ideas for meeting content, please don’t hesitate to contact CPIC (contact@cpicpgx.org). | Kelly will follow-up with more information when available. |
| 2018 PGRN-ASHG Symposium | Mary discussed the upcoming PGRN-ASHG symposium ([https://www.pgrn.org/ashg-2018.html](https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.pgrn.org%2Fashg-2018.html&data=01%7C01%7Ckelly.caudle%40stjude.org%7C4039103beab5455b611708d629515f3e%7C22340fa892264871b677d3b3e377af72%7C0&sdata=L%2FYfyksM%2FltNPDJAJ6wvicZjnQ1tj5TJdDyUQZtyxm0%3D&reserved=0)). | n/a |
| Clinical Societies list | PharmGKB has been working to create a contact list of clinical societies with the plan to send information regarding PharmGKB, PharmVar and CPIC for these organizations to share with their membership and to also propose educational webinars focused on these resources. We are seeking input from CPIC members about additional societies we should contact. Current list attached with these minutes. | If you have any additional clinical societies to add to the list, please send to Kelly (Kelly.caudle@stjude.org). |